Oral LGD1069 retinoid data

LGND (San Diego) said that interim data from a Phase I/IIa trial in 33 patients show that the micronized version of the retinoid LGD1069 shows enhanced bioavailability.

No dose-limiting toxicities were seen up to the highest dose tested, 140 mg/m2. Headache was the primary side effect, seen occasionally. ...